Valuation: PureTech Health plc

Market Cap 427M 373M 342M 319M 605M 40.62B 615M 4.12B 1.6B 19.92B 1.6B 1.57B 68.65B P/E 2026 *
-3.83x
P/E 2027 * -4.25x
Enterprise Value 165M 144M 132M 123M 233M 15.67B 237M 1.59B 616M 7.68B 618M 604M 26.48B EV / Sales 2026 *
23.2x
EV / Sales 2027 * 12.7x
Free-Float
84.5%
Yield 2026 *
-
Yield 2027 * -
1 day-5.91%
1 week-5.62%
Current month-9.61%
1 month-4.46%
3 months+9.91%
6 months-0.32%
Current year-0.64%
1 week 121.45
Extreme 121.448
140.02
1 month 121.45
Extreme 121.448
140.02
Current year 107.4
Extreme 107.4
143.6
1 year 104.71
Extreme 104.712
148
3 years 100.4
Extreme 100.4
238.5
5 years 100.4
Extreme 100.4
410.66
10 years 100.4
Extreme 100.4
447.66
Manager TitleAgeSince
Chief Executive Officer 43 2025-07-14
President 53 2024-04-08
Chief Operating Officer - 2021-07-31
Director TitleAgeSince
Director/Board Member 76 2015-05-07
Director/Board Member 76 2008-12-31
Director/Board Member 73 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
03-12Buy

Founder

112,509 0.0466%
25-09-23Buy

Chief Executive Officer

81,051 0.0337%
25-09-23Buy

Chairman

65,250 0.0272%
Change 5-day change 1-year change 3-year change Capi.($)
-5.91%-5.62%-2.05%-43.16% 427M
+0.36%+5.10%+1.04%+6.65% 48.62B
-1.19%+4.14%+398.92%+591.58% 39.86B
+1.59%+10.74%+25.38%-6.62% 33.91B
+0.99%+6.98%+20.56%+62.87% 32.32B
+1.20%+2.26%+15.60%+32.43% 24.73B
+0.37%+2.65% - - 16.63B
+2.80%+7.41%+71.30%+133.64% 15.52B
+0.99%+1.26%+13.98%+18.72% 13.63B
-2.01%+6.74%+13.92%-29.30% 13.41B
Average -0.05%+6.74%+62.07%+85.20% 23.91B
Weighted average by Cap. +0.54%+7.71%+86.98%+127.83%

Financials

2026 *2027 *
Net sales 7.1M 6.2M 5.7M 5.31M 10.07M 676M 10.24M 68.59M 26.58M 332M 26.66M 26.08M 1.14B 13.47M 11.77M 10.81M 10.08M 19.1M 1.28B 19.43M 130M 50.42M 629M 50.56M 49.47M 2.17B
Net income -124M -108M -99.58M -92.86M -176M -11.81B -179M -1.2B -465M -5.79B -466M -456M -19.97B -96.97M -84.73M -77.81M -72.56M -138M -9.23B -140M -937M -363M -4.53B -364M -356M -15.6B
Net Debt -262M -229M -210M -196M -372M -24.95B -378M -2.53B -981M -12.24B -984M -963M -42.17B -256M -224M -206M -192M -364M -24.4B -370M -2.48B -959M -11.97B -962M -941M -41.23B
Logo PureTech Health plc
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Employees
90
Date Price Change Volume
26-07-02 GBX 124.20 -5.91% 1,612,177
26-07-01 GBX 132.00 -3.93% 267,576
26-06-30 GBX 137.40 +2.54% 888,297
26-06-29 GBX 134.00 +2.13% 445,627
26-06-26 GBX 131.20 -0.30% 202,200
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.753USD
Average target price
5.081USD
Spread / Average Target
+189.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTC Stock